Working… Menu
Trial record 36 of 93 for:    gemtuzumab ozogamicin

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00577694
Recruitment Status : Terminated (funding unavailable)
First Posted : December 20, 2007
Last Update Posted : October 12, 2015
National Cancer Institute (NCI)
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with gemtuzumab may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine when given together with gemtuzumab in treating patients with relapsed or refractory acute myeloid leukemia.

Condition or disease Intervention/treatment Phase
Leukemia Drug: clofarabine Drug: gemtuzumab ozogamicin Phase 1

Detailed Description:



  • Identify the maximum tolerated dose and dose-limiting toxicities of clofarabine when administered with gemtuzumab ozogamicin in patients with refractory acute myeloid leukemia (AML) or with AML that has relapsed within 1 year after cytarabine-containing therapy.


  • Estimate the rates of complete response and/or partial complete response with incomplete platelet recovery in patients treated with this regimen.
  • Estimate the duration of remission in patients treated with this regimen and not proceeding to high-dose therapy and allogeneic stem cell transplantation.
  • Estimate the frequency with which patients enrolled on this study proceed to allogeneic or autologous blood or bone marrow stem cell transplantation.

OUTLINE: This is a dose-escalation study of clofarabine.

Patients receive induction therapy comprising clofarabine IV on days 1-5 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 during course 1 only. Beginning in course 2, after blood counts recover, patients receive consolidation therapy comprising clofarabine IV on days 1-5. Consolidation treatment repeats upon blood count recovery for up to 2 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients in remission after consolidation therapy are followed monthly for the first 6 months, and then every 3-4 months for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Nonrandomized Dose-escalation Study of Clofarabine in Combination With Gemtuzumab Ozogamicin for Relapsed/Refractory Acute Myeloid Leukemia (AML) for Patients Less Than 60 Years-old
Study Start Date : November 2007
Actual Primary Completion Date : July 2010
Actual Study Completion Date : August 2015

Arm Intervention/treatment
single arm study
Drug: clofarabine
Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
Other Name: Clolar

Drug: gemtuzumab ozogamicin
Intravenous, 3mg/m2, Day 1, one cycle
Other Name: Mylotarg

Primary Outcome Measures :
  1. Maximum tolerated dose of clofarabine [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Rate of complete response and/or partial complete response with incomplete platelet recovery [ Time Frame: 3 years ]
  2. Duration of remission [ Time Frame: 5 years ]
  3. Frequency of patients proceeding to allogeneic or autologous blood or bone marrow stem cell transplantation [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

    • Refractory disease, defined as persistent or progressive disease after ≥ 2 induction regimens, including ≥ 1 course of high-dose cytarabine (ARA-C)
    • Relapsed disease that has recurred within 1 year of an ARA-C-containing chemotherapy regimen
  • No CNS disease requiring radiotherapy

    • Patients with neurological symptoms must undergo a lumbar puncture and a CT scan or MRI of the brain to exclude brain metastasis


  • ECOG performance status 0-2
  • Total bilirubin ≤ 2.0 times upper limit of normal (ULN)
  • ALT and AST ≤ 2.0 times the ULN
  • Serum creatinine ≤ 1.0 mg/dL OR glomerular filtration rate > 60 mL/min
  • INR ≤ 1.5 and aPTT within ULN

    • Patients receiving anticoagulation therapy (e.g., warfarin or heparin) are eligible provided anticoagulation therapy can be discontinued or changed to parenteral medications while the platelet count is less than 50,000/mm³
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No concurrent active second primary malignancy (excluding superficial, non-invasive skin cancers)
  • No active bleeding diathesis, not including closely monitored therapeutic anticoagulation
  • No cardiac disease, including any of the following:

    • New York Heart Association class II-IV congestive heart failure
    • Unstable angina (i.e., anginal symptoms at rest)
    • New onset angina (i.e., began within the past 3 months)
    • Myocardial infarction within the past 6 months
  • No active clinically serious infection > grade 2
  • No cerebrovascular accident, including transient ischemic attacks, within the past 6 months
  • No pulmonary hemorrhage ≥ grade 2 within the past 4 weeks
  • No other hemorrhage or bleeding event ≥ grade 3 within the past 4 weeks
  • No known HIV infection or chronic hepatitis B or C
  • No serious non-healing wound or ulcer
  • More than 4 weeks since prior significant traumatic injury
  • No prior history of sinusoidal obstructive syndrome (veno-occlusive disease)


  • More than 4 weeks since prior major surgery or open biopsy
  • More than 100 days since any prior hematopoietic stem cell transplant
  • No concurrent treatment with any other investigational agent for AML

    • Intrathecal chemotherapy administration is allow for central nervous system leukemic infiltration
  • No prior allogeneic stem cell transplant within the past 100 days, with active graft-versus-host disease (GVHD) of any grade, or exposure to immynosuppression for GVHD or prophylaxis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00577694

Layout table for location information
United States, North Carolina
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7295
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Genzyme, a Sanofi Company
Layout table for investigator information
Principal Investigator: Thomas C. Shea, MD UNC Lineberger Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: UNC Lineberger Comprehensive Cancer Center Identifier: NCT00577694     History of Changes
Other Study ID Numbers: LCCC 0708
P30CA016086 ( U.S. NIH Grant/Contract )
CDR0000580801 ( Other Identifier: PDQ number )
First Posted: December 20, 2007    Key Record Dates
Last Update Posted: October 12, 2015
Last Verified: October 2015
Keywords provided by UNC Lineberger Comprehensive Cancer Center:
recurrent adult acute myeloid leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Immunological